These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22872790)

  • 21. Experiences with treprostinil in the treatment of pulmonary arterial hypertension.
    Stream AR; Bull TM
    Ther Adv Respir Dis; 2012 Oct; 6(5):269-76. PubMed ID: 22868690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells.
    Patel JA; Shen L; Hall SM; Benyahia C; Norel X; McAnulty RJ; Moledina S; Silverstein AM; Whittle BJ; Clapp LH
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
    Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
    Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations.
    Ramani G; Cassady S; Shen E; Broderick M; Wasik A; Sui Q; Nelsen A
    Pulm Circ; 2020; 10(3):2045894020923956. PubMed ID: 35154662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy for pulmonary arterial hypertension.
    Parikh V; Bhardwaj A; Nair A
    J Thorac Dis; 2019 Sep; 11(Suppl 14):S1767-S1781. PubMed ID: 31632754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary Arterial Hypertension: New Management Options.
    Huffman MD; McLaughlin VV
    Curr Treat Options Cardiovasc Med; 2004 Dec; 6(6):451-458. PubMed ID: 15496262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
    Chaudhary KR; Deng Y; Suen CM; Taha M; Petersen TH; Mei SHJ; Stewart DJ
    Br J Pharmacol; 2018 Oct; 175(20):3976-3989. PubMed ID: 30098019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
    Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.
    Dandel M; Hetzer R
    Curr Vasc Pharmacol; 2003 Jun; 1(2):171-81. PubMed ID: 15320842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostanoid therapies in the management of pulmonary arterial hypertension.
    LeVarge BL
    Ther Clin Risk Manag; 2015; 11():535-47. PubMed ID: 25848300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension.
    Enderby CY; Burger C
    Ther Adv Chronic Dis; 2018 Sep; 9(9):171-177. PubMed ID: 30181846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
    White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
    Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.